Amended and Restated Non-Employee Director Compensation Policy, adopted by the Board of Directors of the Company on October 9, 2017, amended as of May 31, 2018 and further amended as of December 19, 2019
Exhibit 10.3
MOLECULAR TEMPLATES, INC.
AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION
POLICY
ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 9, 2017 AMENDED AS OF
MAY 31, 2018
FURTHER AMENDED EFFECTIVE AS OF DECEMBER 19, 2019
Each member of the board of directors (the “Board”) of Molecular Templates, Inc. (the “Company”) who is not an employee of the Company or any parent or subsidiary of the Company (each, a “Non-Employee Director”) will be eligible to receive cash and equity compensation as set forth in this Molecular Templates, Inc. Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation described in this Policy will be paid or granted, as applicable, automatically and without further action of the Board to each Non-Employee Director who is eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company. This Amended and Restated Policy became effective on October 9, 2017 (the “Effective Date”), was amended effective as of May 31, 2018 and amended further as of December 19, 2019, and will remain in effect until it is revised or rescinded by further action of the Board. Capitalized terms not explicitly defined in this Policy but defined in the 2018 Equity Incentive Plan (as may be amended from time to time, the “2018 Plan”) will have the same definitions as in the 2018 Plan.
Board or Committee | Type of Fee | Amount (Per Year) | |||
Board | Chair Retainer Fee | $ | 70,000 | ||
Non-Chair Member Retainer Fee | $ | 40,000 | |||
Audit Committee | Chair Retainer Fee | $ | 15,000 | ||
Non-Chair Member Retainer Fee | $ | 7,500 | |||
Compensation Committee | Chair Retainer Fee | $ | 10,000 | ||
Non-Chair Member Retainer Fee | $ | 5,000 | |||
Nominating and | Chair Retainer Fee | $ | 8,000 | ||
Corporate Governance Committee | Non-Chair Member Retainer Fee | $ | 4,000 |
To the extent that any taxable reimbursements are provided to a Non-Employee Director, they will be provided in accordance with Section 409A of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations and other guidance thereunder and any state law of similar effect, including, but not limited to, the following provisions: (i) the amount of any such expenses eligible for reimbursement during the Non-Employee Director’s taxable year may not affect the expenses eligible for reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense must be made no later than the last day of the Non-Employee Director’s taxable year that immediately follows
the taxable year in which the expense was incurred; and (iii) the right to any reimbursement may not be subject to liquidation or exchange for another benefit.
Each Initial Option Grant and Annual Option Grant which is assumed by a successor corporation in connection with a Corporate Transaction will be appropriately adjusted immediately after such Corporate Transaction to apply to the number and class of securities which would have been issuable to the Participant as a result of the consummation of such Corporate Transaction had the Initial Option Grant or Annual Option Grant been exercised immediately prior to
such Corporate Transaction. Appropriate adjustments will also be made to the exercise price payable per share under each outstanding Initial Option Grant and Annual Option Grant, provided that the aggregate exercise price payable for such securities will remain the same. To the extent the actual holders of the Common Stock receive cash consideration for their Common Stock in consummation of the Corporate Transaction, the successor corporation may, in connection with the assumption of the outstanding Initial Option Grants and Annual Option Grants, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Corporate Transaction.